{"gao_id": "GAO-21-282", "published": "2021-03-29T12:00:00Z", "released": "2021-04-28T08:00:00Z", "summary": "We estimated the prices for 20 brand-name drugs in the U.S. for 2020 and compared them to the publicly available prices for the same drugs in Australia, Canada, and France. We found U.S. retail level prices were 2 to 4 times higher than prices in the comparison countries. However, clouding this comparison are the rebates and confidential discounts offered on some drugs. Our estimate took...", "title": "Prescription Drugs: U.S. Prices for Selected Brand Drugs Were Higher on Average than Prices in Australia, Canada, and France", "topics": ["Pharmacy", "Insurance deductible", "Supply chain management", "Health Care", "Consumers", "Health insurance", "Beneficiaries", "Health benefits", "Medicare", "Drug prices", "Research and development", "Pharmaceutical industry", "Medicaid", "Drugs", "Prescription drugs", "Federal spending"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-21-282", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-21-282-highlights.pdf"}, {"title": "Full Report (65 pages)", "url": "https://www.gao.gov/assets/gao-21-282.pdf"}, {"title": "Accessible PDF (89 pages)", "url": "https://www.gao.gov/assets/720/713431.pdf"}]}